$STAB On High Alert! Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19 Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)
FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to the U.S. Food and Drug Administration (FDA) of its pilot study protocol for STAT-205 treatment of post-acute (long-haul) COVID-19.
News 
Market Data 
Discover 
